AIDS Malignancy Consortium (AMC)

The AIDS Malignancy Consortium (AMC) is a National Cancer Institute-supported clinical trials group founded in 1995 to support innovative trials for AIDS-associated malignancies. The AMC is composed of 14 main Clinical Trials Sites and their affiliates, and an Operations and Statistical Center. The AMC is committed to enhancing therapeutic options for patients with AIDS-associated malignancies. The AMC is composed of over 30 Clinical Trials Sites and their affiliates, five Working Groups, an Administrative Office, an Operations and Data Management Center, and a Statistical Center. Collectively, these components develop and oversee the scientific agenda, manage the groups’ portfolio of clinical trials and other scientific-based studies, and help to develop new protocols.

Four of the Working Groups deal with cancers that affect HIV-positive patients—Kaposi’s Sarcoma, Lymphoma, Human Papillomavirus-related Cancers (for example, anal and cervical cancers), and Non-AIDS Defining Cancers (for example, lung cancer, head and neck cancer, liver cancer). The Laboratory Working Group oversees the Central Laboratories of the AMC and develops laboratory studies to answer important scientific questions related to cancer in HIV-positive patients. In addition, all of the groups within the AMC are working to expand the AMC globally and to conduct clinical trials for AIDS-related cancers in diverse patient populations in resource limited areas such as South America, India, and Africa.